Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings has reported Total Non-Current Liabilities for 3 years, with the latest figure at $150.4 million in Q4 2023.

• For the quarter ending Q4 2023, Total Non-Current Liabilities fell 15.16% year-over-year to $150.4 million; the trailing twelve-month figure through Dec 2023 stood at $150.4 million (down 15.16% YoY), and the FY2023 full-year result was $150.4 million, down 15.16% from the prior year.
• Total Non-Current Liabilities for Q4 2023 stood at $150.4 million, down from $176.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $177.3 million in Q4 2022, with the low at $128.5 million in Q1 2021.
• Historically, Total Non-Current Liabilities has averaged $153.0 million across 3 years, with a median of $144.3 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 17.09% — and 2023, when it climbed 22.41%.
• Arcturus Therapeutics Holdings' Total Non-Current Liabilities stood at $174.0 million in 2021, then gained by 1.87% to $177.3 million in 2022, then declined by 15.16% to $150.4 million in 2023.
• The last three Total Non-Current Liabilities figures came in at $150.4 million (Q4 2023), $176.6 million (Q3 2023), and $144.2 million (Q2 2023), per Business Quant data.